RecruitingPhase 4NCT07829029

Ancillary Nocturnal Urinary Symptoms Analyses for TRIUMPH

Ancillary Nocturnal Urinary Symptom Investigation in the TRIUMPH Trial

Sponsor

University of California, San Francisco

Enrollment

270 participants

Start Date

Oct 4, 2022

Study Type

INTERVENTIONAL

Conditions

Nocturia Nocturnal Urinary Incontinence

Summary

The TRIUMPH study is a randomized, double-blinded, 3-arm, parallel-group trial designed tocompare the effects of anticholinergic bladder therapy versus a) beta-3-adrenergic agonistbladder therapy and b) no bladder pharmacotherapy on cognitive, urinary, and other aging-related functional outcomes in ambulatory older women with urgency-predominant urinaryincontinence and either normal or mildly impaired cognitive function at baseline.

Eligibility

Sex: FEMALEMin Age: 60 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Mirabegron, a drug called Placebo, and others for people with nocturia and nocturnal urinary incontinence. The study is currently recruiting participants at 1 location. People eligible for this study include women aged 60 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.